<DOC>
	<DOCNO>NCT00002409</DOCNO>
	<brief_summary>The purpose study see HIV-education course help under-represented , HIV-infected patient . This study examine area faithfulness drug regimen , level HIV blood , health status .</brief_summary>
	<brief_title>The Effect Teaching HIV-Infected Patients About HIV Treatment</brief_title>
	<detailed_description>Following initial screening , eligible patient treat open-label Combivir plus abacavir 24 week . Patients randomize undergo education intervention , Tools Health Empowerment ( T.H.E . ) course plus counseling , routine counseling ( control group ) . Measurements evaluation assessment immunologic effect , adherence , health outcome perform entry ( Day 1 ) Weeks 2 , 5 , 8 , 12 , 16 , 24 .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Lamivudine , zidovudine drug combination</mesh_term>
	<criteria>Inclusion Criteria Patients must : Documented confirm HIV infection . Limited experience antiretrovirals . CD4+ lymphocyte cell count 50 cells/mm3 14 day prior study drug administration . HIV1 plasma RNA 40 copies/ml less 100,000 copies/ml within 14 day prior study drug administration . Ability read , comprehend , record information fifthgrade English . Ability attend 4 session T.H.E . course Weeks 14 . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Patients suffer serious medical condition diabetes , congestive heart failure , cardiomyopathy , cardiac dysfunction would compromise safety patient . Malabsorption syndrome gastrointestinal dysfunction may interfere drug absorption render patient unable take oral medication . Acute chronic active hepatitis . Concurrent Treatment : Excluded : Treatment foscarnet agent require documented activity HIV1 vitro . Patients follow prior condition exclude : A clinical diagnosis AIDS , accord 1993 Centers Disease Control ( CDC ) AIDS surveillance definition . ( CD4 cell count 200 cells/mm3 consider AIDSdefining . ) History allergy study drug . Prior Medication : Excluded : History antiretroviral use . Patients history sequential nucleoside monotherapy exclude , patient total antiretroviral history exceed 6 month . Required treatment immunomodulating agent , systemic corticosteroid , interleukin , vaccine , interferon , within 4 week prior study entry , HIV immunotherapeutic vaccine within 3 month prior entry . Asthmatic patient use inhaled corticosteroid eligible enrollment . Prior Treatment : Excluded : Radiation therapy cytotoxic chemotherapeutic agent receive within 4 week prior entry . Risk Behavior : Excluded : Current alcohol illicit drug use may interfere ability comply dose schedule protocol evaluation assessment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 1999</verification_date>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>Patient Education</keyword>
	<keyword>Patient Compliance</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Viral Load</keyword>
	<keyword>abacavir</keyword>
</DOC>